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SummAry Autoimmune disturbances and metabolic abnormalities ob-
served in vitiligo, a disease of still unclear etiology, may provide evidence on 
the systemic nature of the disease. The aim of the study was to assess func-
tional and morphological parameters of the liver and spleen, as well as the 
lipid profile in vitiligo-affected children, in order to ascertain whether any 
metabolic abnormalities or structural changes in these organs accompanied 
the course of vitiligo.  The study included 34 patients with vitiligo hospitalized 
at the Department of Dermatology at the Medical University of Lublin and a 
control group of 35 healthy individuals, aged 7-15 years. Children with the ac-
tive phase of vitiligo and at least 6 month history of vitiligo lesions were stud-
ied. Ultrasound examination of the liver and spleen enabled assessment of the 
size and parenchyma of the organs. Liver and spleen functions were assessed 
by means of the following additional examinations: blood test, transaminases, 
protein electrophoresis, lipid profile, autoantibodies, and HCV antibodies. The 
size of the liver was not significantly different in the vitiligo and control groups. 
The ultrasonographic pictures of the spleen revealed no abnormalities in or-
gan size and structure. The concentration of HDL-cholesterol was significantly 
lower, whereas the concentration of LDL-cholesterol was significantly higher 
in patients with vitiligo than in healthy controls. The value of the LDL/HDL ra-
tio was significantly higher in vitiligo patients. The results of our study indicate 
lipid disturbances in vitiligo-affected children. Since no structural and func-
tional abnormalities in the liver and spleen were found, it seems likely that 
lipid disturbances in vitiligo may result from disturbed metabolic processes in 
the adipose tissue as well as from oxidative stress.
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InTroDuCTIon
Vitiligo is an acquired depigmenting skin disease 
of still unclear, multifactorial etiopathogenesis. Even 
though the disease does not lead to physical ail-
ments, its disfiguring effect may be responsible for 
stigmatization and decreased quality of life of the pa-
tients. A recent study has revealed that psychological 
disturbances, such as obsession and phobia, are more 
prevalent in vitiligo patients in whom autoimmune 
markers are present, confirming the hypothetical 
psychoneuro-endocrine-immunological pathogen-
esis of vitiligo (1). This finding seems to be suggestive 
of a systemic nature of vitiligo in which the clinical 
and psychological manifestations are interwoven and 
interdependent. In vitiligo, various autoantibodies are 
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present and trigger autoimmune co-morbidities such 
as alopecia areata, autoimmune thyroid disease, Ad-
dison’s disease, pernicious anaemia, diabetes mellitus, 
and myasthenia gravis (2,3). When diabetes mellitus 
is diagnosed in addition to vitiligo, and if other com-
ponents of a metabolic syndrome are detected, may 
eventually lead to the development of cardiovascu-
lar diseases as well as cardiovascular death. A recent 
study has found that insulin resistance as well as some 
lipid profile disturbances may be observed in patients 
with vitiligo (4). Since research into immunological and 
metabolic abnormalities indicates that these may oc-
cur in patients with vitiligo, it seems essential to check 
these patients for such disturbances or abnormalities. 
Metabolic processes take place in bodily organs such 
as the liver, spleen, and pancreas, so these organs 
should therefore be subjected to close scrutiny in pa-
tients with vitiligo. However, it still remains unclear 
when these abnormalities start occurring in the course 
of vitiligo, and if they can appear in children with viti-
ligo. So far, few published reports have provided infor-
mation on metabolic disturbances detected in adults 
suffering from vitiligo, let alone children. 
The aim of this study was to assess the size and 
structure of the liver and spleen using ultrasound, 
along with the functional parameters of the organs 
and a lipid profile in children with vitiligo.
mATErIAL AnD mETHoDS
The study included 34 children with vitiligo hospi-
talized in the Department of Dermatology, Venereol-
ogy and Paediatric Dermatology at the Medical Uni-
versity of Lublin, Poland, as well as 35 healthy subjects. 
All the studied children had negative history of lipid 
disturbances and familial dislipidaemia. None of the 
patients was on special diet nor had any special di-
etary habits. The age of the children in the vitiligo and 
control group was 7-15 years, the mean age being 10.9 
and 10.5 years respectively. Only those children with 
vitiligo who had the active phase of the disease and 
at least six months of skin lesions exacerbation were 
included in the study. Information on the children’s 
gender, duration of vitiligo, type of disease, total skin 
involvement (Figure1), family history, and presence of 
concomitant autoimmune disease was obtained from 
patients’ records and physical examination (Table 1). 
The children who had a history of heart disease, arteri-
al hypertension, diabetes mellitus, obesity, or systemic 
diseases were excluded from the study.
Vitiligo activity was assessed with the use of Viti-
ligo Disease Activity (VIDA) Score which is a six-point 
scale with the following grading: VIDA Score +4 – ac-
tivity of 6 weeks or less duration; +3 – activity of 6 
weeks to 3 months; +2 – activity of 3 – 6 months; +1 
– activity of 6 – 12 months; 0 – stable for 1 year or 
more; and -1 – stable with spontaneous repigmenta-
tion since 1 year or more (5).
In both the vitiligo and control group the liver and 
spleen ultrasound examinations were performed us-
ing Siemens Sonoline Elegra ultrasonoghraph (Sie-
mens, Erlangen, Germany) with 3.5 HHz and 5 MHz 
transducers of a convex type. The size and parenchy-
ma of the organs was assessed. In order to determine 
liver size, measurements in three vertical lines were 
Characteristics Category Parameter Vitiligo Healthy children p
Number of patients n 34 35
Gender
Male % 61.8 45.7
>0.05


























* Abbreviations: Min – minimum, Max – maximum, M – mean, SD – standard deviation.
Table 1. Demograpical and clinical characteristics of children with vitiligo and healthy children*
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Min-Max M±SD Min-Max M±SD
Liver size
Liver anterior axillary line (cm) 9.0-14.8 12.4±1.5 10.1-16.0 12.4±1.5 >0.05
Liver medioclavicular line (cm) 7.0-13.1 10.7±1.4 8.7-14.0 11.1±1.4 >0.05
Liver sternal line (cm) 6.4-12.8 9.1±1.3 6.8-12.0 9.5±1.3 >0.05
Spleen size
Spleen longitudinal section (cm) 7.0-13.0 9.3±1.4 7.2-12.0 9.4±1.4 >0.05
Spleen transverse section (cm) 2.8-5.1 3.6±0.5 2.8-4.5 3.5±0.5 >0.05
Blood tests
HBG (g/dL) 10.7-15.5 13.0±1.1 11.4-14.8 13.3±0.9 >0.05
RBC (M/mm3) 3.6-5.4 4.4±0.4 3.9-4.9 4.4±0.3 >0.05
WBC (K/mm3) 3.8-12.4 6.8±2.4 4.2-11.4 7.0±1.6 >0.05
Plt (K/mm3) 140.8-330.0 248.2±80.8 176.0-343.2 245.0±68.1 >0.05
Transaminases
ALT (IU/L) 9.0-33.6 19.7±7.9 6.0-38.4 17.7±8.4 >0.05
AST (IU/L) 5.0-38.0 19.0±8.0 9.3-36.0 22.6±8.0 >0.05
Electrophoresis of proteins
Total proteins (g/L) 6.0-7.8 7.0±0.5 6.5-7.9 7.2±0.4 >0.05
A/G 0.9-1.8 1.4±0.2 0.9-1.7 1.3±0.2 >0.05
Albumin (%) 48.0-64.3 58.2±4.4 47.8-62.4 56.9±3.7 >0.05
Alpha1-globulins (%) 3.4-6.6 4.4±1.1 3.3-7.3 4.7±1.3 >0.05
Alpha2-globulins (%) 7.4-13.7 10.3±2.2 7.8-15.7 11.2±2.0 >0.05
Beta-globulins (%) 10.4-16.0 12.7±1.8 9.9-16.5 13.0±1.8 >0.05
Gamma-globulins (%) 7.8-22.1 14.3±4.3 11.8-17.1 14.3±1.7 >0.05
Lipid profile
Total cholesterol (mg/dL) 125.8-199.5 170.8±15.2 112.8-190.6 161.6±21.3 0.055
HDL-cholesterol (mg/dL) 32.8-65.0 49.4±8.0 37.5-75.5 53.8±7.7 0.001
LDL-cholesterol (mg/dL) 70.8-134.8 107.2±15.8 52.0-123.4 92.4±18.9 0.030
LDL/HDL 1.3-3.1 2.2±0.5 0.9-2.5 1.7±0.4 0.000
Triglyceride (mg/dL) 44.7-146.0 104.3±29.9 44.6-150.0 101.3±27.1 >0.05
Phospholipids (mg/dL) 137.6-216.0 174.9±17.5 112.6-222.0 171.9±25.8 >0.05
HDLF (mg/dL) 59.5-108.0 81.1±13.0 63.2-102.3 81.7±10.9 >0.05
LDLF (mg/dL) 51.4-108.0 74.8±14.4 38.1-111.0 74.0±16.7 >0.05
*Abbreviations: Min – minimum, Max – maximum, M – mean, SD – standard deviation. HDL – high-density lipoprotein, LDL 
– low-density lipoprotein, LDLF – LDL cholesterol/phospholipides; HDLF – HDL cholesterol/phospholipids, HGB – hemoglo-
bin , RBC – red  blood cells, WBC – white blood cells, Plt – platelets)
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performed: in the right front axillary line, in the cen-
tral line of the right clavicle, and in the central line of 
the body in the section going through the long axis 
of the aorta. The spleen was measured in two dimen-
sions, longitudinal and transverse.
Blood samples were collected from both group 
after a 12-hour fast. The following examinations were 
performed: blood test, transaminases, glucose, elec-
trophoresis of proteins, lipid profile, autoantibodies, 
and HCV (hepatitis C virus) antibodies. Concentra-
tions of lipid profile were assayed using bio-Merieoux 
(Craponne, France) kits: LDL (Low-density lipopro-
tein) Cholesterol/Phospholipides; HDL (High-density 
lipoprotein) Cholesterol/Phospholipides; Cholesterol 
enzymatique PAP; Phospholipides enzymatique PAP; 
and Triglycerides enzymatique PAP UV 250, in accor-
dance with the manufacturer’s instructions.
Statistical analyses were performed using STA-
TISTICA Software (StatSoft, Tulsa, OK, USA). Cat-
egorical variables were given as percentages and 
compared with a χ2 test. For numerical variables, 
minimums, maximums, means, and standard devia-
tions were estimated. Numerical variables were com-
pared between group using independent-samples 
Student’s test, Cochran-Cox test, or Mann-Whitney 
U test. In order to examine the correlation between 
Table 2. Comparison of ultrasonographic and laboratory examinations between  children with vitiligo and 
healthy children*
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ultrasonographic liver size and lipid profile param-
eters, Pearson’s correlation coefficient was used. A p-
value<0.05 was considered statistically significant.
rESuLTS
Table 1 presents demographic information and 
medical data concerning both groups of children. No 
significant differences were observed with reference 
to the height, weight, and body mass index (BMI) of 
children with vitiligo and the healthy children. Three 
children with vitiligo (8.82%) had a positive family 
history of vitiligo. In one child, concomitant autoim-
mune thyroid disease was present. Nineteen children 
(55.88%) had a common type of vitiligo, whereas 15 
(44.12%) had a focal type of vitiligo. None of the chil-
dren presented mucosal vitiligo changes.
The 3 mean values of liver size were not signifi-
cantly different in the experimental and control group 
(Figure 2). Ultrasonographic assessment did not re-
veal any abnormalities in the size and structure of the 
organ (Figure 3). There were no significant differences 
between patients with vitiligo and healthy individu-
als in the following parameters: blood test, transami-
nases, glucose, and electrophoresis of proteins.
Lipid profile analysis revealed a significantly low-
er HDL-cholesterol concentration (p=0.001) and a 
significantly higher LDL-cholesterol concentration 
(p=0.030) in patients with vitiligo in comparison with 
the healthy children. Moreover, the value of the LDL/
HDL ratio was significantly higher in patients with viti-
ligo than in healthy individuals (p=0.000096). The dif-
ference in the total cholesterol concentration between 
the vitiligo and control group was close to statistical 
significance (p=0.055). The concentrations of other 
lipids including triglyceride, HDL-phospholipids, and 
LDL-phospholipids, were not statistically different be-
tween the experimental and control group (Figure 4, 
Table 2). The statistical analysis of possible correlation 
between ultrasonographic liver size and lipid profile 
parameters revealed a positive correlation between 
the size of the liver measured in the anterior axillary 
line and the LDL/HDL ratio, a phenomenon which was 
not observed in healthy children (Figure 5).
DISCuSSIon
The process of lipid digestion would be incom-
plete without the contribution of the bile salts as well 
as pancreatic lipase, therefore, the role of the liver and 
pancreas must be perceived as indispensible in the 
normal lipid metabolism. 
Having reacted with water-soluble proteins (usu-
ally apoproteins), lipids, which are  insoluble in blood, 
are transported as chylomicrons or lipoproteins. Next, 
they are absorbed by the liver cells to produce various 
lipoprotein forms, such as VLDL, LDL, which carry the 
lipids to the body cells, whereas their excess will be 
invariably converted into the adipose tissue. Another 
form of lipoprotein, such as HDL, which transports the 
lipids back to the liver, has an important role in reverse 
cholesterol transport (6). 
According to some recent reports, the adipose tis-
sue not only accumulates the excess energy but it is 
also an important organ fulfilling the endocrine (se-
cretory) function. The white fat tissue, for example, 
secretes a number of bioactive substances (hormones, 
cytokines, other proteins) known as adipokines, e.g. 
leptin, adiponectin, resistin, vaspin, visfatin as well as 
Figure 1. Histogram showing total skin involvement 

















Fig. 1. Histogram showing total skin involvement in the 34 cildren with vitiligo 
Figure 2. Box and whisker plots comparing liver size 
in children with vitiligo and healthy controls 
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 Liver medioclavicular line
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Figure 3. Box and whisker plots comparing spleen 
size in children with vitiligo and healthy controls 
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Figure 4. Box and whisker plots comparing lipids in the experimental and control group. Min – minimum, Max 
– maximum, SD – standard deviation. HDL – high-density lipoprotein, LDL – low-density lipoprotein, LDLF – LDL 
cholesterol/phospholipides; HDLF – HDL cholesterol/phospholipids
TNFα, IL-6, MCP-1, which are involved in various pro-
cesses such as glucose and lipid metabolism as well as 
immunity. Nevertheless, it appears that should any dis-
turbances in their secretion occur, they may contribute 
to the development of the metabolic syndrome and 
cardiovascular disease. Thus, it is quite plausible that 
obesity is associated with insulin resistance, hypergly-
cemia, dyslipidaemia, hypertension and prothrombot-
ic and proinflammatory states (7, 8). 
 The number of recent studies on various con-
comitant disturbances in patients with vitiligo indi-
cates a growing interest among specialists who have 
started seeing vitiligo not merely as a separate entity 
but rather as a much more complex condition with a 
potential to trigger the development of generalized 
abnormalities of a systemic nature. Thus, it seems 
essential that once vitiligo has been diagnosed, the 
doctor should be on the lookout for possible co-
morbidities. Vitiligo pathogenesis, in which genetic, 
immunological, autoimmunological, cytotoxic, neu-
ronal, and inflammatory factors are involved, is com-
plex and still unclear, which may explain a wide spec-
trum of its systemic manifestations. Karadag et al. (4) 
have found that even in patients with vitiligo that are 
free of diabetes a higher insulin resistance as well as 
higher insulin and C-peptide levels were observed in 
comparison with the control group. The same study 
also reported a statistically significant decrease in 
HDL-cholesterol concentration in patients with viti-
ligo, and an increase in LDL/HDL ratio. Our study, per-
formed on a group of children, generated similar re-
sults; however, we detected a statistically significant 
higher LDL-cholesterol concentration.
In 2000, we published a report on lipid serum pa-
rameters in vitiligo-affected girls, in which we dem-
onstrated a statistically relevant decrease in HDL cho-
Pietrzak et al. Acta Dermatovenerol Croat
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lesterol as well as increased triglyceride concentra-
tions in the group of girls with vitiligo. Additionally, a 
tendency increased LDL cholesterol and decreaseed 
HDL phospholipid concentrations in patients with 
vitiligo was noted (9).
These findings may reflect some ongoing ab-
normal metabolic processes in patients with vitiligo 
which should be regarded as significant contributing 
factors worth considering in the  management of pa-
tients with vitiligo.
Interestingly, Noel et al. (10) describe a 55- year-old 
male in whom treatment with high doses of simvastatin 
resulted in the regression of vitiligo. This unexpected 
effect of HMG-Co reductase inhibitor may indicate that 
lipid profile abnormalities are in some way connected 
with the presence and severity of vitiligo. The authors 
concluded that the use of statins as immuno-modula-
tors could be beneficial in the treatment of vitiligo. 
The above mentioned lipid and glucose abnormali-
ties are components of a metabolic syndrome, a condi-
tion which may lead to the development of cardiovas-
cular complications. Numerous researchers have made 
an attempt to evaluate the prevalence of metabolic dis-
turbances and cardiovascular disease in inflammatory 
conditions, including skin and rheumatological diseas-
es such as psoriasis, psoriatic arthritis, rheumatoid ar-
thritis, lupus erythematosus, or lichen planus. Studies 
have shown that, among others, proinflammatory 
cytokines (tumor) necrosis factor (TNF), interleukin 1, 
interleukin 6 (IL-1, IL-6) and other inflammatory factors 
(e.g. C-reactive protein) are involved in evoking insulin 
resistance as well as other metabolic complications and 
atherosclerosis (11). In a very recent report, Karadag et 
al. (12) demonstrated that patients with vitiligo had 
higher levels of homocysteine, which not only inhibits 
tyrosinase, but also increases cardiovascular risk.
In 2010, Nunes and Martins (13) published a case re-
port presenting a male patient with long-lasting vitiligo 
in whom a myocardial infarction was diagnosed. The 
patient had also been instructed to avoid sun expo-
sure. Laboratory investigations performed on the pa-
tient revealed, among others, a low plasma 25-hydroxy 
vitamin D level, which is known to be associated with 
cardiovascular disease. The authors concluded that viti-
ligo could be associated with hypovitaminosis D.
According to recent reports, the role of melanocytes 
in the development of metabolic complications should 
be considered in greater detail. Melanocytes are found 
not only in the skin and hair follicles but also in the 
retinal pigment epithelium cells as well as in some cells 
of the inner ear and other parts of the central nervous 
system. This provides explanation for the occurrence of 
such clinical syndromes as Alezzandrini’s syndrome or 
Vogt-Koyanagi-Harada’s syndrome (10). Melanocytes 
Figure 5. Scatter diagrams investigating the relation-
ships between LDL/HDL ratio and liver size, separate-
ly for the children with vitiligo and healthy controls 
(HDL - High-density lipoprotein, LDL - Low-density 
lipoprotein)
have also been detected in adipose tissue where they 
take part in anti-inflammatory reactions and in the re-
duction or binding of reactive oxygen species (ROS), 
acting as scavengers of free radicals and other oxidative 
species. While it has been shown that melanogenesis is 
higher in obese humans in comparison with individuals 
with healthier BMI values (7), this is beyond the scope 
of the present study since we have excluded obese chil-
dren from our study. The lack of metabolic disturbances 
such as obesity, hypertension, diabetes mellitus, insulin 
resistance in the studied children as well as a relatively 
short vitiligo history (M 2.1±0.8 years) may explain the 
not statistically different values of the total cholesterol, 
triglyceride, HDL-phospholipids and LDL-phospholip-
ids between the studied and control groups as well 
as the absence of a more advanced lipid disturbances’ 
development.
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As previously mentioned, there is a strong correla-
tion between melanocytes and oxidative stress, i.e. the 
higher the activity of melanogenesis the lower the ox-
idiative stress. However, there have been no studies on 
the contents or activity of melanocytes in the adipose 
tissue or on the metabolic processes taking place in 
vitiligo-affected patients. It is possible that lipid abnor-
malities detected in patients with vitiligo are the result 
of disturbed metabolic processes in the adipose tissue. 
Interestingly, Page et al. (14) have suggested a hy-
pothesis that agonists of melanin production such as 
melanocyte-stimulating hormone (α-MSH) or its syn-
thetic analogues should be tested as potential thera-
peutic agents for prevention of development of meta-
bolic syndromes.
Since the synthesis of carbohydrates, proteins, and 
lipids takes place in the liver, one might expect its in-
volvement in vitiligo. However, it is worth noting that 
in our ultrasonographic assessment both the liver and 
spleen remained unchanged.
As oxidative stress is known to be present in the 
course of vitiligo, it is held responsible for the cytotoxic 
effects that it exerts on melanocytes, e.g. high H2O2 
levels that are found throughout the epidermis (15). 
The processes promoting lipid peroxidation that occur 
in the epidermis, and perhaps in the adipose tissue as 
well, may be a plausible explanation for the lipid ab-
normalities detected in our study.
ConCLuSIonS
The results of our study are indicative of lipid dis-
turbances in vitiligo-affected children .
Ultrasound examination revealed no abnormalities 
with reference to the size and structure of both the liv-
er and spleen, nor did biochemical investigation reveal 
any dysfunctions of the liver and spleen.
Since no structural and functional abnormalities in 
the liver and spleen were found, it seems plausible that 
lipid disturbances in vitiligo may result from disturbed 
metabolic processes in the adipose tissue.
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